Do we really need yet another JAKi? COURAGE-RA RCT phIII JAK1-selective Zemprocitinib RA bDMARDs IR Primary endpoint ACR20 at wk24 79.1% vs 39.7% PBO (p<0.0001) wk24 ACR50: 55.8% vs 22.0% wk 24 DAS28-CRP ≤3.2: 67.0% vs 23.4% No new safety signal Looks very similar to other https://t.co/b0RMBWl4Xx